One mechanism for the reappearance of G protein-coupled receptors after agonist activation is microtubule-based transport. In pressure-overload cardiac hypertrophy, there is downregulation of G protein-coupled receptors and the appearance of a densified microtubule network extensively decorated by a microtubule-associated protein, MAP 4. Our hypothesis is that overdecoration of a dense microtubule network with this structural protein, as in hypertrophied myocardium, would impede receptor recovery. We tested this hypothesis by studying muscarinic acetylcholine receptor (mAChR) internalization and recovery after agonist stimulation in neuroblastoma cells. Exposure of cells to carbachol, a muscarinic receptor agonist, decreased membrane receptor binding activity. After carbachol withdrawal, receptor binding recovered toward the initial value. When microtubules were depolymerized before carbachol withdrawal, mAChR recovery was only 44% of that in intact cells. Cells were then infected with an adenovirus containing MAP 4 cDNA. MAP 4 protein decorated the microtubules extensively, and receptor recovery upon carbachol withdrawal was reduced to 54% of control. Thus muscarinic receptor recovery after agonist exposure is microtubule dependent, and MAP 4 decoration of microtubules inhibits receptor recovery.
G PROTEIN-COUPLED CELL MEMBRANE RECEPTORS (GPCRs) respond to a wide variety of stimuli. For the purpose of our primary interest, the regulation of cardiac muscle biology, these receptors can be considered in terms of their effects on cAMP-dependent protein kinase, where they may couple to adenyl cyclase either via the stimulatory G protein G s to increase cAMP, via the inhibitory G protein G i to decrease cAMP, or instead act on phospholipase C independently of cAMP via the G q/11 protein family. The homeostatic compensatory roles of GPCRs become especially important in diseased myocardium, where the activity of the G s -coupled receptors tends to be decreased, and those of G i -coupled and G q/11 -coupled receptors are less consistently altered (2, 3, 5) . Any reduction in activity is mediated in the short term by phosphorylation of GPCRs during either agonist-dependent homologous desensitization or agonistindependent heterologous desensitization (5) . In the longer term, as in cardiac disease states, reduced GPCR activity is also mediated by diminished receptor density, or downregulation, which is especially well defined for the ␤-adrenoceptor (2, 26) . While a number of causes for GPCR downregulation have been established (3), the potential role of diminished GPCR recovery after agonist-induced GPCR internalization has not been fully defined.
In substantially pressure-overloaded, hypertrophied, and failing myocardium, there is a striking increase in the density and stability of the cardiocyte microtubule network (10, 34) , and these microtubules are heavily decorated by microtubule-associated protein 4 (MAP 4) (30) . Given this observation, together with the facts that activated GPCRs are recycled within endocytic vesicles (5) , that vesicular transport occurs at least partly via motor ATPases along microtubules (13, 16) , and that microtubule decoration by structural microtubule-associated proteins inhibits this trafficking (4, 11) , we wondered whether the GPCR downregulation seen in hypertrophied and failing myocardium might be based to some extent on the abnormalities of the extramyofilament cytoskeleton that we had observed.
As an initial simplifying approach to this specific question, we applied it here to a well-characterized model of GPCR dynamics, muscarinic acetylcholine receptor (mAChR) recovery in neuroblastoma cells (7, 19, 20, 22, 27) by examining the effects of MAP 4 decoration of microtubules on this process. Furthermore, as an approach to a more comprehensive question, we wished to use this model system to ask whether altered cytoskeleton-based intracellular trafficking might be a potential mechanism for the regulation of some facets of GPCR behavior in general.
MATERIALS AND METHODS

MAP 4 antibody.
To generate the MAP 4 antibody, we made a bacterial expression construct using the 1-740 NH 2-terminal residues of human MAP 4 (8). The recombinant protein, which had a hexahistidine tag inserted at the COOH terminus, was overexpressed in Escherichia coli, purified on a nickel-chelate affinity column, and submitted to SDS-PAGE. The purified protein band was excised, eluted from the gel, and sent to Lampire Biological Laboratories for preparation of a rabbit polyclonal MAP 4 antibody.
Cell culture. Murine neuroblastoma N1E-115 cells from American Type Culture Collection (passages 5-10) were grown in a 5% CO 2 atmosphere at 37°C on tissue culture dishes in DMEM supplemented with 10% fetal bovine serum, 4 mM L-glutamine, 4.5 g/l glucose, and 100 U/ml each of penicillin and streptomycin. Cells were seeded into six-well plates at a density of 10 5 cells/35-mm well, grown for 3 days until 80-90% confluent, and maintained in serum-free medium thereafter.
[N-methyl- 3 H]scopolamine binding assays. Cell surface mAChR density was measured in N1E-115 cells via ligand binding assays using the hydrophilic, plasmalemma-impermeant muscarinic antagonist [N-methyl- 3 H]scopolamine (NMS; 78 mCi/mM) (6, 18) . The binding assays were performed at 4°C to avoid both receptor endocytosis and reappearance of the receptors on the cell surface after internalization (14) . Nonspecific binding was determined by the addition of 2 M atropine, a high-affinity muscarinic receptor antagonist, to triplicate wells and represented Ͻ5% of total counts. This value was subtracted from the total binding to obtain specific plasmalemma-bound [ 3 H]NMS. Immunofluorescence confocal microscopy. N1E-115 cells were extracted in 1% Triton X-100 for 1 min and rinsed three times in microtubule stabilization buffer (2 mM EGTA, 0.1 mM EDTA, 1 mM MgSO4, and 100 mM MES; pH 6.75) (25) . The cells were fixed and stained as previously described (30) .
Construction of recombinant adenoviruses. The pTG3602 plasmid system for generating replication-defective recombinant adenoviruses via homologous recombination with a bacterial system (9, 29) was used to construct adenoviruses for MAP 4 and ␤-galactosidase (␤-Gal) overexpression in N1E-115 cells. The MAP 4 cDNA construct was generated by PCR using specific oligonucleotide primers and full-length human MAP 4 cDNA (a gift from J. C. Bulinski, Columbia University, Columbia, NY) as a template (4) . The primer for the NH 2 terminus also contained a sequence for an epitope tag of amino acids 410-419 of human c-Myc. In addition, KpnI restriction sites were included at the end of each primer. The sequence of the full-length MAP 4 construct was confirmed by DNA sequencing. The KpnI fragment was subcloned into an adenovirus shuttle vector designed to produce a high level of constitutive expression by replacing E1 adenoviral sequences with a gene cassette consisting of the cytomegalovirus promoter element, the multiple cloning site, and the simian virus 40 polyadenylation signal. After homologous recombination of a NheI-ApaI fragment of this shuttle vector with adenovirus type 5 DNA whose EIA region was deleted (pTG3602), the recombinant adenovirus DNA containing the MAP 4 expression cassette was linearized and transfected into the human epithelial kidney (HEK) cell line HEK-293 using lipofectamine reagent. The adenovirus was plaque purified, expanded, and titered via the detection of visible plaque formation in HEK-293 monolayers.
Adenovirus-mediated gene transfer. N1E-115 cells were infected with MAP 4 adenovirus (AdMAP 4) in serum-free medium (2 ml/35-mm plate) at the indicated multiplicity of infection (MOI) for 24 h. The cells were rinsed in serum-free medium and incubated for a further 48 h to permit transgene expression. Companion dishes were infected at the same MOI with ␤-Gal adenovirus (Ad␤-Gal), a similarly constructed adenovirus expressing the ␤-Gal gene (29) . A MOI range of 10-100 plaque-forming units (pfu)/cell of AdMAP 4 or Ad␤-Gal caused Ͼ90% infection after 48 h, as determined by immunofluorescence microscopy using antibodies to the c-Myc epitope tag on the transfected MAP 4 or to ␤-Gal; there was no observable cytotoxicity.
Immunoblots. Cell lysates were prepared for immunoblotting as we previously described (30) . The blots were incubated for 16 h with the primary antibody. After blots were incubated with biotinylated secondary antibody, specific protein bands were detected using avidin-biotinylated horseradish peroxidase in conjunction with enhanced chemiluminescence.
Data analysis. Means Ϯ SE are given for the numerical data. Any statistical comparisons are specified in the individual figures.
RESULTS
Characteristics of the cell model. To establish the location of the mAChR in unstimulated N1E-115 neuroblastoma cells, the cells were exposed both to tetrameth- Bottom: N1E-115 cell cultures were preincubated with or without 2 mM carbachol for 16 h. Fresh medium with 2 mM carbachol and either 1 M colchicine or 1 mM cytochalasin B was then added. After a 2-h incubation, the cells were washed with carbachol-free DMEM, and incubation was continued for 9 h to assay receptor recovery to the plasmalemma. [Nmethyl- 3 H]scopolamine (NMS) binding was determined as described in MATE-RIALS AND METHODS. cpm, Counts per minute. Each point is the mean of 6 determinations. Statistical comparisons were by one-way ANOVA followed by Scheffé's S-procedure. Bar, 5 m. * P ϭ not significant (NS) for a difference from carbachol alone; †P Ͻ 0.01 for a difference from recovery alone;
‡P ϭ NS for a difference from carbachol alone; §P ϭ NS for a difference from recovery alone.
ylrhodamine-Con A, a plasma membrane marker (Fig.  1A) , and to an antibody to the M 2 subtype of the mAChR (Fig. 1B) . Colocalization of the resultant signals to the plasma membrane is evident in Fig. 1 , C and D.
Role of microtubules and microfilaments in mAChR recovery. To determine whether microtubules and/or microfilaments are required for mAChR recycling, N1E-115 cells were treated with carbachol, a nonsubtype-selective mAChR agonist, to activate and internalize these receptors. Recovery of cell surface receptor density was then followed over time in the control state and after microtubule or microfilament depolymerization. The normal microtubule network in these cells ( Fig. 2A ) was reduced to a scattering of residual microtubules after a 2-h exposure to 1 M colchicine (Fig.  2B) . The normal actin microfilament architecture (Fig.  2C ) was completely disrupted after a 2-h exposure to 1 mM cytochalasin B (Fig. 2D) . The summary data in Fig. 2 show that incubation of N1E-115 cells with 2 mM carbachol for 16 h led to a decline in the density of cell surface mAChR to 24 Ϯ 1% of that in control cells incubated without carbachol; mAChR density recovered to 80 Ϯ 4% of the control value 9 h after carbachol withdrawal. When instead the microtubules were depolymerized before carbachol withdrawal, mAChR density recovered to only 35 Ϯ 9% of control, as shown previously for another GPCR, the ␤-adrenoceptor (21) . In contrast, with microfilament disruption before carbachol withdrawal, receptor density recovered to 79 Ϯ 7% of control, a value concordant with that for cells with an intact cytoskeleton. Thus microtubules have a critical role in the recovery of endocytosed mAChRs, whereas microfilaments do not.
Adenovirus-mediated MAP 4 expression and microtubule decoration. Before the effects of microtubule decoration with MAP 4 on mAChR recovery were in- vestigated, it was necessary to ascertain in neuroblastoma cells whether MAP 4 protein expressed by the transgene decorated the microtubules efficiently and to identify an adenoviral MOI sufficient for efficacious MAP 4 translation. Normal microtubule network architecture was retained in N1E-115 cells infected with Ad␤-Gal at a MOI of 100 pfu/cell (Fig. 3A) . In cells infected with AdMAP 4 at a MOI of 100 pfu/cell, there was extensive microtubule network decoration by transfected human MAP 4 (Fig. 3B) . The data shown in Fig. 3C , generated using antibodies to the c-Myc epitope tag on the transfected MAP 4 and to endogenous glyceraldehyde-3-phosphate dehydrogenase (GAPDH), show that robust and essentially equivalent expression of MAP 4 protein occurs in N1E-115 cells at an AdMAP 4 MOI range of 10-100. As shown in Fig. 4 , with the use of a MAP 4 antibody in cells infected with either Ad␤-Gal or AdMAP 4, there was virtually no MAP 4 detected in the ␤-Gal-infected cells. Thus the MAP 4 protein expressed at an AdMAP 4 MOI of 100 was almost exclusively the product of the transgene. Because no cytotoxicity was seen at the higher MAP 4 adenovirus concentration, an AdMAP 4 MOI of 100 was used for the studies that follow.
mAChR recovery. The studies to this point using a radiolabeled mAChR ligand clearly indicate a decrease in cell surface receptor density after agonist exposure. But it is also possible that this decrease is due to some extent to a change in mAChR affinity rather than being solely due to a change in mAChR number. First, for this reason, second, to establish visually agonist-induced mAChR internalization and subsequent recovery after agonist withdrawal, and, finally, to preclude significant nonspecific effects of adenoviral infection on this process, N1E-115 cells were infected with Ad␤-Gal at a MOI of 100 pfu/cell, allowed to express the transgene for 48 h, and then probed with mAChR antibody. At this point, the mAChRs were localized to the plasma membrane (Fig. 5, A and B) . When instead the cells were exposed to carbachol for 16 h before fixation, the internalized mAChRs were distributed throughout the cytoplasm (Fig. 5, C and D) . Finally, 9 h after the carbachol was withdrawn, mAChRs were once again present at the plasma membrane (Fig. 5, E and F) . This response of the mAChR to agonist stimulation and withdrawal is identical to that observed in control N1E-115 cells not exposed to adenovirus (data not shown).
When, in contrast, this same protocol was repeated with AdMAP 4 infection of N1E-115 cells at a MOI of 100 pfu/cell, the results were quite different. Whereas the basal plasma membrane location of mAChRs (Fig.  6, A and B) was the same as that in control or Ad␤-Gal-infected cells, as well as mAChR internalization after agonist stimulation (Fig. 6, C and D) , mAChRs failed to return to the plasma membrane after agonist withdrawal (Fig. 6, E and F) . Importantly, total cellular protein synthesis was not altered from the control by this protocol in N1E-115 cells infected by either Ad␤-Gal or AdMAP 4 at this MOI (data not shown). Thus MAP 4 expression in neuroblastoma cells, at a level that results in extensive MAP 4 decoration of the microtubules (Fig. 3) , disrupts the recovery of activated mAChRs to the cell surface.
This visual impression was then confirmed via quantitative pharmacological assays. The initial value for , lane 2) at a MOI of 100 pfu/cell. For the immunoblot, cells were harvested and homogenized in MAP 4 lysis buffer consisting of 2% NP-40, 100 mM Tris ⅐ HCl, 10 mM EGTA, 0.35 M NaCl, 1 mM Na3VO4, 0.5 mM phenylmethylsulfonyl fluoride, 10 g/ml aprotinin, 10 g/ml leupeptin, 2 g/ml pepstatin A, 2 M transepoxysuccinyl-L-leucylamido-(4-guanidino) butane, and 10 mM dithiothreitol. After incubation on ice for 20 min, the cell lysates were centrifuged at 16,000 g for 10 min at 4°C. The supernatants, after centrifugation a second time at 16,000 g for 30 min at 4°C, were mixed with an equal volume of 2ϫ SDS sample buffer and boiled. An equal amount of total protein (20 g) was loaded in each lane. Our MAP 4 antibody (see MATERIALS cell surface mAChR density, defined as binding activity, and the extent of agonist-induced mAChR internalization were the same for N1E-115 cells infected with either Ad␤-Gal or AdMAP 4 at the same MOI (Fig. 7A) . However, over a MOI range of 0-100 AdMAP 4 pfu/ cell, there was an inverse relationship between viral titer and the extent of mAChR recovery upon agonist withdawal (Fig. 7A) . Figure 7B shows this dose-response behavior for AdMAP 4 titer versus receptor recovery in terms of expressed MAP 4 protein. There is a significant inverse linear relationship between the concentration of MAP 4 protein and the extent of receptor recovery to the cell membrane after agonist withdrawal.
A similar effect of MAP 4 expression in N1E-115 cells was seen in terms of the rate of mAChR recovery to the cell surface after agonist withdrawal (Fig. 8) . Assuming a constant rate of microtubule-based (35) mAChR recovery to the cell surface, MAP 4 expression reduced this rate by 52% from that seen with ␤-Gal expression. Furthermore, the immunoblots in Fig. 8 show that, as was the case for N1E-115 cells expressing ␤-Gal (data not shown), the amount of mAChR protein did not decrease during the slowed receptor trafficking in N1E-115 cells expressing MAP 4, even when de novo mAChR synthesis during recovery was blocked by cycloheximide. Thus slowed receptor trafficking does not appear to be due to reduced receptor numbers.
The data in Fig. 9 show that in untreated control N1E-115 cells, inhibition of protein synthesis has no effect on the earlier phase (up to 3 h) of receptor recovery after agonist exposure, when preexisting receptors are being recycled, but it does prevent the later (after 3 h) appearance of newly synthesized mAChRs on the cell surface. In conjunction with Fig. 8, which shows that the percent inhibition of mAChR trafficking by MAP 4 is similar at all time points Ն3 h, this indicates that microtubule decoration by MAP 4 inhibits both the recylcing of preexistent mAChRs and the externalization of newly synthesized mAChRs.
DISCUSSION
The intent of this study was to address the question of whether extensive microtubule decoration with a structural MAP would inhibit the recovery of an activated GPCR. For the cell-receptor combination studied here, this question was answered in the affirmative. That is, the neuroblastoma cell plasmalemmal mAChRs (Fig.  1 ) internalize upon agonist exposure and then return to the cell surface upon agonist withdrawal (Fig. 2) . This recovery process is microtubule dependent but not microfilament dependent (Fig. 2) . Decoration of the microtubules with MAP 4 (Figs. 3 and 4) inhibits this recovery process (Figs. 5 and 6) in terms of both the extent of receptor recycling (Fig. 7) and the rate at which this recovery occurs (Fig. 8) . This altered recovery is due to the exogenous MAP 4 (Fig. 4) , because, as would be expected for the undifferentiated neuroblastoma cells used here (23) , expression of native MAP 4 is virtually undetectable, but there is robust expression of the MAP 4 transgene and microtubule decoration by its protein product.
This data set is specifically informative of M 2 mAChR properties. That is, although N1E-115 cells express both the M 1 and M 2 mAChR subtypes (28), we found here in N1E-115 cells that, as in other cell types (17) , the M 2 but not the M 1 subtype exhibits internalization in response to agonist exposure (data not (Fig.  5) . However, in contrast to the extensive outward transport of internalized M2 mAChRs seen after agonist withdrawal in N1E-115 cells overexpressing ␤-Gal (Fig. 4, E and F shown). This differing internalization behavior of the two mAChR subtypes is based on five amino acids that are present in the M 2 subtype but absent from the M 1 subtype and that are essential for agonist-induced dynamin-independent receptor internalization (31) . In contrast to other GPCRs that are transported along microfilaments but not along microtubules (36), we show here that M 2 mAChRs are transported along microtubules, as has again been found in another cell type (27) , but not along microfilaments.
More interesting in the context of our original question, however, are the effects of MAP 4 microtubule decoration on GPCR trafficking. The recovery of cell surface M 2 mAChRs after agonist exposure tends to be rather slow (6) , with 50% recovery requiring ϳ8 h in N1E-115 cells (32) . This recovery has two phases (6) . The first phase of protein synthesis-independent recovery reflects the recycling of internalized M 2 mAChRs to the cell surface. In the present data, Fig. 8 shows that MAP 4 overexpression impedes the reappearance of M 2 mAChRs on the cell surface at the earlier time points of 3 and 6 h, such that receptor recycling was inhibited. The second phase of protein synthesis-dependent recovery accounts for the balance of the reappearance of M 2 mAChRs on the cell surface after agonist exposure. In the present data, Fig. 9 shows that inhibition of protein synthesis does, in fact, inhibit the later but not the earlier phase of mAChR recovery. In Fig. 8 , it is apparent that MAP 4 overexpression also inhibits mAChR recovery to the same extent throughout this later phase. Thus both phases of the trafficking of mAChRs to the cell surface after agonist-induced receptor internalization were inhibited both by microtubule depolymerization and by MAP 4 decoration of the microtubules. Such recovery required an intact microtubule network, and the extent of recovery was inversely related to the level of expression of the MAP 4 transgene.
The M 2 mAChR internalizes after agonist stimulation via mechanisms that are common to a number of Fig. 8 . Rate of M2 mAChR outward transport after agonist-induced internalization is reduced by MAP 4 overexpression. N1E-115 cells were infected with either Ad␤-Gal or AdMAP 4 at a MOI of 100 pfu/cell. The cells were then treated with 2 mM carbachol for 16 h, washed 3 times, and allowed to recover for 0, 3, 6, or 9 h at 37°C before determination of [ 3 H]NMS binding. A: the results show that overexpressed MAP 4 reduces the rate of cell surface mAChR recovery significantly and to a similar degree at each time point Ն3 h (* P Ͻ 0.01 for a difference between the Ad␤-Gal and AdMAP 4 groups via one-way ANOVA followed by Scheffé's S-procedure). B: for the immunoblots, identically treated cells were washed 3 times and incubated in DMEM with (bottom) or without (top) 20 g/ml cycloheximide and then harvested at the times indicated. They were immunoblotted as described using C-18 M2 mAChR primary antibody. other GPCRs (12) : agonist binding to a GPCR causes both the relevant signaling event via heterotrimeric G protein interaction and receptor desensitization via GPRC kinase-mediated receptor phosphorylation that leads to ␤-arrestin binding to the receptor, and ␤-arrestin interaction with clathrin-coated vesicles then leads directly to receptor translocation to an endosomal compartment wherein the GPCR is dephosphorylated. If not degraded, the GPCR is then transported outward to the plasmalemma in its resensitized native state via mechanisms that have heretofore been poorly understood (12) . It is the extent of the microtubule dependence of this outward transport of the M 2 mAChR that has been of particular interest here. In this regard, two aspects of microtubule properties are relevant.
First, it is now well established that microtubule dynamics are controlled in part by structural MAPs (15) . MAP 4, which in contrast to other MAPs is expressed ubiquitously, has a COOH-terminal microtubule-binding domain consisting of three to five repeats of an 18-amino acid motif that is well conserved among structural MAPs (8, 15) . We show here that overexpressed MAP 4 binds to microtubules in the N1E-115 cell, and it is clear that microtubule-bound MAP 4 causes a marked increase in microtubule stability (24) . However, as shown in another study of microtubulebased transport (4), we found that microtubule stabilization by taxol had no effect on M 2 mAChR recovery (data not shown). Thus MAP 4 effects on microtubule stability do not appear to have an important role in the inhibitory effects of MAP 4 on AChR recovery that we see in N1E-115 cells.
Second, it is also well established that microtubules serve as tracks for intracellular transport via motor ATPases of the kinesin and dynein superfamilies (1, 16) . Decoration of microtubules by tau, a neuronal MAP, decreases the attachment frequency of these motor proteins to the microtubule (33), likely via steric inhibition (4) , such that the run length of these motor proteins along the microtubule, and thus net vectorial transport of their associated cargoes, are decreased. Especially pertinent in the context of the present study of GPCR outward transport, this effect is most pronounced for kinesin-dependent microtubule plus-end directed transport to the cell periphery (33) .
In summary, recovery of the activated mAChR is microtubule dependent, and it is inhibited by MAP 4 decoration of the microtubules. Of further general interest is the question of whether this behavior applies to other GPCRs in other cell types, either in vitro or more importantly in vivo. That is, altered cytoskeletonbased intracellular trafficking, whether via microtubules or via other cytoskeletal polymers, may well be one mechanism for the regulation of GPCR behavior in general. Of further specific interest for our understanding of cardiac hypertrophy and failure, the present data provide a rational basis for asking the question of whether the GPCR downregulation seen there might be related in part to the dense, stabilized, and heavily MAP 4-decorated cardiocyte microtubule network that we find in pressure-overload cardiac hypertrophy and failure.
